The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke.
Ceren EyiletenLucia SharifZofia WicikDaniel JakubikJoanna Jarosz-PopekAleksandra SoplinskaMarek PostulaAnna CzlonkowskaAgnieszka Kaplon-CieslickaDagmara M Mirowska-GuzelPublished in: Molecular neurobiology (2020)
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors that plays a crucial role in the development of the nervous system while supporting the survival of existing neurons and instigating neurogenesis. Altered levels of BDNF, both in the circulation and in the central nervous system (CNS), have been reported to be involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and ischemic stroke. MicroRNAs (miRNAs) are a class of non-coding RNAs found in body fluids such as peripheral blood and cerebrospinal fluid. Several different miRNAs, and their target genes, are recognized to be involved in the pathophysiology of neurodegenerative and neurovascular diseases. Thus, they present as promising biomarkers and a novel treatment approach for CNS disorders. Currently, limited studies provide viable evidence of miRNA-mediated post-transcriptional regulation of BDNF. The aim of this review is to provide a comprehensive assessment of the current knowledge regarding the potential diagnostic and prognostic values of miRNAs affecting BDNF expression and its role as a CNS disorders and neurovascular disease biomarker. Moreover, a novel therapeutic approach in neurodegenerative diseases and ischemic stroke targeting miRNAs associated with BDNF will be discussed.
Keyphrases
- multiple sclerosis
- amyotrophic lateral sclerosis
- stress induced
- cerebrospinal fluid
- peripheral blood
- atrial fibrillation
- healthcare
- mass spectrometry
- genome wide
- spinal cord
- gene expression
- white matter
- ms ms
- dna methylation
- spinal cord injury
- cancer therapy
- risk assessment
- brain injury
- subarachnoid hemorrhage
- drug delivery
- combination therapy